Lucis
Summary active Updated May 27, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Investors
Founders
About
Lucis is a Paris-based preventive health platform that combines blood biomarker analysis with AI to deliver personalised, science-based health recommendations 12. The platform analyses more than 110 blood biomarkers across metabolic health, hormones, cardiovascular risk, inflammation, and nutrient levels 1.
Founded in 2025 by Maxime Berthelot and Baptiste Debever, Lucis reached 10,000 users in under a year 12. Among users who completed a six-month follow-up, the company reports that 75% improved at least three biomarkers without medication 1.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2025-12 | Seed | €7.2M | — | Y Combinator and others 2 |
| 2026-05-26 | Series A | €17.1M | Singular | General Catalyst, Y Combinator, angels including Céline Lazorthes (Resilience), Manu Lecomte, and Runna investors 12 |
The Series A brings total funding to approximately €24M 2. The company plans to expand into Spain, Germany, and Italy by the end of 2026 1.
What Investors Say
No independently sourced investor quotes found at this time.
What Founders Say
No independently sourced founder testimonials found at this time.
Sources
-
“YC-backed French preventive health platform Lucis raises €17.3 million Series A led by Singular,” EU-Startups, May 26, 2026. https://www.eu-startups.com/2026/05/yc-backed-french-preventive-health-platform-lucis-raises-e17-3-million-series-a-led-by-singular/↩↩↩↩↩↩
-
“Lucis raises $20M Series A to expand AI-driven preventive healthcare platform,” Tech.eu, May 26, 2026. https://tech.eu/2026/05/26/lucis-raises-20m-series-a-to-expand-ai-driven-preventive-healthcare-platform/↩↩↩↩↩